Abstract
PURPOSE
Radiotherapy techniques have been utilized to treat keratinocyte skin carcinoma (KSC).
The objective of this study was to report the results of patients with KSC treated
with HDR brachytherapy, with a variety of techniques and applicators. A statistical
analysis of clinical, radiobiological, and technical factors has been made to analyze
those factors related to skin acute toxicity, focused on acute epithelitis G3.
METHODS AND MATERIALS
Between February 2005 and August 2020, 93 patients with 120 histologically proven
KSC have been treated in our Institution. BT treatment has been performed using superficial
BT/plesiotherapy (Valencia applicator (22%), flaps (48%), customized molds (4%) or
interstitial techniques (26%)). The indications of BT were primary/definitive in 38
treatments (32%) or adjuvant/postoperative in 82 (68%). In 14 (17%) of the 82 operated
patients a skin graft. Mean comparison t tests were performed for quantitative variables,
and percentage comparison Chi2 tests for qualitative. Multivariate binomial logistic
regression models were done.
RESULTS
Median follow-up was 36.5 months (range 5–141). Local control was achieved in 110
treatments (92%). Acute toxicity, dermatitis, was G1 7%; G2, 57% and G3 38%. The main
factors statistically associated to the appearance of dermatitis G3 were the total
dose, the volume treated, and the use of manufactured flaps. The main protective factor
against dermatitis G3 was implant of skin graft.
CONCLUSIONS
In KSC BT the use of manufactured flap is accompanied by greater EG3, only with a
relationship with the volume of treatment and total dose.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to BrachytherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
REFERENCE
- Prevalence of a history of skin cancer in 2007: Results of an incidence-based model.Arch Dermatol. 2010; 146: 279-282
- Immunologic characteristics of nonmelanoma skin cancers: Implications for immunotherapy.Am Soc Clin Oncol Educ Book. 2020; 40: 1-10
- Non-melanoma skin cancer mortality in Spain: A predictive model up to 2044.J Clin Med. 2021; 10: 5750
- Basal cell carcinoma of the face: Surgery or radiotherapy? Results of a randomized study.Br J Cancer. 1997; 76: 100-106
- European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC). Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines.Eur J Cancer. 2019; 118: 10-34
- Definitive and postoperative radiation therapy for basal and squamous cell cancers of the skin: Executive summary of an American Society for Radiation Oncology Clinical Practice guideline.Pract Radiat Oncol. 2020; 10: 8-20
- Aspects of dosimetry and clinical practice of skin brachytherapy: The American Brachytherapy Society working group report.Brachytherapy. 2015; 14: 840-858
- GEC-ESTRO ACROP recommendations in skin brachytherapy.Radiother Oncol. 2018; 126: 377-385
- Recommendations of the Spanish brachytherapy group (GEB) of Spanish Society of Radiation Oncology (SEOR) and the Spanish Society of Medical Physics (SEFM) for high-dose rate (HDR) non melanoma skin cancer brachytherapy.Practice Guideline Clin Transl Oncol. 2018; 20: 431-442
- Fractionated high dose rate brachytherapy moulds–A precise treatment for carcinoma of the pinna.Radiother Oncol. 1998; 48: 277-281
- Treatment of skin carcino mas of the face by high-dose-rate brachytherapy and custom-made surface molds.Int J Radiat Oncol. 2000; 47: 95-102
- High-dose-rate (HDR) plesiotherapy with custom-made moulds for the treatment of non-melanoma skin cancer.Clin Transl Oncol. 2009; 11: 760-764
- The initial experience of electronic brachytherapy for the treatment of non-melanoma skin cancer.Radiat Oncol. 2010; 5: 87
- Treatment of facial cutaneous carcinoma with high-dose rate contact brachytherapy with customized molds.Brachytherapy. 2011; 10: 221-227
- HDR brachytherapy for superficial non-melanoma skin cancers.J Med Imaging Radiat Oncol. 2013; 57: 212-217
- Non-melanoma skin cancer treated with HDR valencia applicator: Clinical outcomes.J Contemp Brachyther. 2014; 6: 167-172
- Prognostic factors in squa mous cell lip carcinoma treated with high-dose-rate brachytherapy.Head Neck. 2014; 36: 1737-1742
- Hypofractionated high-dose-rate plesiotherapy in nonmelanoma skin cancer treatment.Brachytherapy. 2015; 14: 859-865
- Non-melanoma skin cancer treated with high-dose-rate brachytherapy: a review of literature.J Contemp Brachyther. 2016; 8: 533-540
- Two years results of electronic brachytherapy for basal cell carcinoma.J Contemp Brachyther. 2017; 9: 251-255
- Custom mold applicator high-dose-rate brachytherapy for nonmelanoma skin cancer-An analysis of 273 lesions.Brachytherapy. 2018; 17: 601-608
- Computed tomography-based flap brachytherapy for non-melanoma skin cancers of the face.J Contemp Brachyther. 2021; 13: 51-58
- Non-melanoma skin cancer treated by contact high-dose-rate radiotherapy (Brachytherapy): A mono-institutional series and literature review.In Vivo. 2021; 35: 2313-2319
- Design and evaluation of a HDR skin applicator with flattening filter.Med Phys. 2008; 35: 495-503
- Commissioning and quality assurance procedures for the HDR Valencia skin applicators.J Contemp Brachyther. 2016; 8: 441-447
- The use of high frequency skin ultrasound in non-melanoma skin cancer.J Contemp Brachyther. 2021; 13: 483-491
- Depth determination of skin cancers treated with superficial brachytherapy: Ultrasound vs. histopathology.J Contemp Brachyther. 2015; 6: 356-361
- Novel simple templates for reproducible positioning of skin applicators in brachytherapy.J Contemp Brachyther. 2016; 8: 344-348
Van der Laarse R and De Boer R. 1990 Computerized high dose rate brachytherapy treatment planning. Brachytherapy HDR-LDR. In Proceedings Brachytherapy Meeting: Remote afterloading. State of the Art. ed. Martinez, Orton and Mould; 170–183.
National Institutes of Health. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03.2010.
- 21 years of biologically effective dose.Br J Radiol. 2010; 83: 554-568
- Repopulation effects.in: Dale RG Jones B Radiobiological modelling in radiation oncology. The British Institute of Radiology, London2007 (Fox)
- (John)An R companion to applied regression.SAGE Publications, Thousand Oaks, CA2019
- Acute and late complications and toxicities of skin brachytherapy.Brachytherapy. 2021; 20: 1041-1052
- High dose rate brachytherapy with customized applicators for malignant facial skin lesions.Cancer Radiother. 2016; 20: 341-346
- High-dose-rate brachytherapy in treatment of non-melanoma skin cancer of head and neck region: Preliminary results of a prospective single institution study.J Contemp Brachyther. 2018; 10: 115-122
- The role of personalized Interventional Radiotherapy (brachytherapy) in the management of older patients with non-melanoma skin cancer.J Geriatr Oncol. 2019; 10: 514-517
- High-dose-rate brachytherapy for non-melanoma skin cancer using tailored custom moulds - A single-centre experience.Contemp Oncol (Pozn). 2021; 25: 12-16
- Tumor control and cosmetic outcome of weekly iridium-192 high-dose-rate brachytherapy for nonmelanoma skin cancers in the elderly.Brachytherapy. 2021; 20: 818-827
Article info
Publication history
Published online: November 11, 2022
Accepted:
October 7,
2022
Received in revised form:
September 9,
2022
Received:
June 7,
2022
Footnotes
Disclosures: The authors report no proprietary or commercial interest in any product mentioned or concept discussed in this article.
Identification
Copyright
© 2022 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
